Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus Type-1 mono-infection and co-infection with hepatitis C Virus

Virology Journal

Volumn 9, Issue , 2012, Pages

  Kamihira, Shimeru ^a   Usui, Tetsuya ^b   Ichikawa, Tatsuki ^a   Uno, Naoki ^a,b   Morinaga, Yoshitomo ^a,b   Mori, Sayaka ^b   Nagai, Kazuhiro ^b   Sasaki, Daisuke ^a,b   Hasegawa, Hiroo ^a,b   Yanagihara, Katsunori ^a,b   Honda, Takuya ^a   Yamada, Yasuaki ^a,b   Iwanaga, Masako ^c   Kanematu, Takashi ^a   Nakao, Kazuhiko ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c Kwassui Women's College   (Japan)

Author keywords

HCV; HTLV 1; IL 3; IL 28B; SNP

Indexed keywords

INTERLEUKIN 28B; VIRUS RNA; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MESSENGER RNA;

ARTICLE; BLOOD; CELL LINE; DOWN REGULATION; GENE FREQUENCY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN TISSUE; MIXED INFECTION; NONHUMAN; PROTEIN EXPRESSION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION; ALLELE; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS C; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNOLOGY; VIROLOGY; VIRUS LOAD;

HEPATITIS C VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1;

ALLELES; CELL LINE; COINFECTION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HTLV-I INFECTIONS; HUMANS; INTERLEUKINS; RISK FACTORS; RNA, MESSENGER; VIRAL LOAD;

EID: 84857022067     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-40     Document Type: Article

References (21)

1. Human T-lymphotropic virus type-I influence on hepatotropic virus infections and the subsequent development of hepatocellular carcinoma. Kamihira S, Yamada Y, Sohda H, Atogami S, Tomonaga M, Egawa S, Fujii M, Chifu K, Cancer Detect Prev 1994 18 5 329 334 7812978 (Pubitemid 2156042)
2. Antibody to the human T-lymphotropic virus type 1 (HTLV-1) envelope protein Gp46 in patients co-infected with HCV and HTLV-1. Takeoka H, Furusyo N, Toyoda K, Murata M, Sagara Y, Kashiwagi S, Hayashi J, Am J Trop Med Hyg 2007 77 1 192 196 17620653 (Pubitemid 351844374)
3. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, Mueller N, J Infect Dis 2000 181 1 35 41 10.1086/315177 10608748 (Pubitemid 30049030)
4. Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Kohno T, Yamada Y, Akamatsu N, Kamihira S, Imaizumi Y, Tomonaga M, Matsuyama T, Cancer Sci 2005 6 8 527 33 (Pubitemid 41387306)
5. Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. Kishihara Y, Furusyo N, Kashiwagi K, Mitsutake A, Kashiwagi S, Hayashi J, J Infect Dis 2001 184 9 1114 1119 10.1086/323890 11598833 (Pubitemid 33010463)
6. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB, Nature 2009 461 7262 399 401 10.1038/nature08309 19684573
7. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M, Nat Genet 2009 41 10 1105 1109 10.1038/ng.449 19749757
8. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP, Nat Immunol 2003 4 1 69 77 12483210 (Pubitemid 36109115)
9. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. Li M, Liu X, Zhou Y, Su SB, J Leukoc Biol 2009 86 1 23 32 10.1189/jlb.1208761 19304895
10. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M, Nature 2009 461 7265 798 801 10.1038/nature08463 19759533
11. Aberrant p53 protein expression and function in a panel of hematopoietic cell lines with different p53 mutations. Kamihira S, Terada C, Sasaki D, Yanagihara K, Tsukasaki K, Hasegawa H, Yamada Y, Eur J Haematol 2009 82 4 301 307 10.1111/j.1600-0609.2009.01211.x 19220422
12. Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive cells. Usui T, Yanagihara K, Tsukasaki K, Murata K, Hasegawa H, Yamada Y, Kamihira S, Retrovirology 2008 22 5 34
13. IL-28B and the control of HCV infection. Baloopa S, Thomas David L, Thio Chloe L, Gastroenterology 2010 139 6 1865 1875 10.1053/j.gastro.2010.10.004 20950615
14. IL-28B polymorphism does not determine outcomes of HBV or HIV infection. Maureen PM, Ying Q, James J G, Shehnaz KH, regoly DK, Keith HW, Susan B, 2010 202 11 1749 1753
15. Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica. Birmann BM, Breen EC, Stuver S, Cranston B, Martínez-Maza O, Falk KI, Okayama A, Hanchard B, Mueller N, Hisada M, Int J Cancer 2009 124 3 614 21 10.1002/ijc.24012 18989900
16. German Anti-D Study Group.: A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J, Gastroenterology 2010 139 5 1586 92 1592.e1 10.1053/j.gastro.2010.07.005 20637200
17. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J, Nat Genet 2009 41 10 1100 1104 10.1038/ng.447 19749758
18. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR, J Virol 2006 80 9 4501 4509 10.1128/JVI.80.9.4501-4509.2006 16611910
19. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. Osterlund P, Veckman V, Sirén J, Klucher KM, Hiscott J, Matikainen S, Julkunen I, J Virol 2005 79 15 9608 9617 10.1128/JVI.79.15.9608-9617.2005 16014923 (Pubitemid 41022304)
20. Comparative Analysis of the Lambda-Interferons IL-28A and IL-29 regarding Their Transcriptome and Their Antiviral Properties against Hepatitis C Virus. Diegelmann J, Beigel F, Zitzmann K, Kaul A, Göke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S, PLoS One 2010 5 12 15200 10.1371/journal.pone.0015200 21170333
21. FN - treated dendritic cells specifically induce proliferation of Foxp3-expressing suppressor T-cells. Mennechet FJD, Uze D, Blood 2006 107 4417 4423 10.1182/blood-2005-10-4129 16478884 (Pubitemid 43801368)